Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. (PLX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · PLX · as of Jun 8, 2026
Activity summary
Buy transactions
1
P-Purchase only
Sell transactions
1
12 Months
Buy/Sell ratio
1.00
Buy/Sell (by trades)
Overall sentiment
Protalix BioTherapeutics, Inc. insiders have shown mixed buying and selling activity over the past 12 Months.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
PLX insider buying and selling by quarter
PLX insider selling · PLX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · PLX ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
PLX executive sell shares · PLX board member insider trading · PLX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Dec 19, 2025 | Bashan Dror PRESIDENT AND CEO · Director | Purchase | 56,000 | $101K | Form 4 |
| Nov 18, 2025 | Bar-Shalev Amos Director | Sale | 168 | $314 | Form 4 |
| Sep 3, 2025 | Forster Eliot Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Melincoff Gwen A Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Boudes Pol F Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Elze Christian Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Schwartz Aharon Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Ben Zvi Shmuel Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Bar-Shalev Amos Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Naos Yaron Sr. VP, Operations | Award | 25,000 | — | Form 4 |
| Sep 3, 2025 | Bashan Dror PRESIDENT AND CEO · Director | Award | 195,000 | — | Form 4 |
| Jun 10, 2025 | Schwartz Aharon Director | Purchase | 129,000 | $206K | Form 4 |
| Sep 23, 2024 | Rubin Eyal Sr. VP and CFO | Award | 99,010 | — | Form 4 |
| Apr 1, 2024 | Bashan Dror PRESIDENT AND CEO · Director | Award | 263,960 | — | Form 4 |
| Oct 19, 2023 | Bashan Dror PRESIDENT AND CEO · Director | Purchase | 16,129 | $23K | Form 4 |
| Oct 19, 2023 | Bashan Dror PRESIDENT AND CEO · Director | Purchase | 48,387 | $68K | Form 4 |
| Aug 15, 2023 | Bashan Dror President and CEO · Director | Award | 800,000 | — | Form 4 |
| Aug 15, 2023 | Rubin Eyal Sr. VP and CFO | Award | 201,903 | — | Form 4 |
| Aug 15, 2023 | Hayon Yael VP, Research & Development | Award | 35,115 | — | Form 4 |
| Aug 15, 2023 | Naos Yaron Sr. VP, Operations | Award | 187,344 | — | Form 4 |
| Jan 3, 2023 | Schwartz Aharon Director | Purchase | 110,000 | $156K | Form 4 |
| Apr 11, 2022 | Bashan Dror President and CEO | Purchase | 68,000 | $102K | Form 4 |
| Feb 25, 2022 | Rubin Eyal Sr. VP and CFO | Award | 121,951 | — | Form 4 |
| Feb 25, 2022 | Bashan Dror President and CEO · Director | Award | 637,531 | — | Form 4 |
| Jun 2, 2021 | Dexcel Pharma Technologies Ltd. 10 percent owner | Sale | 61,211 | $157K | Form 4 |
Bashan Dror
PRESIDENT AND CEO · Director
Date
Dec 19
Shares
56,000
Price
$1.81
Value
$101K
Bashan Dror
PRESIDENT AND CEO · Director
Date
Sep 3
Shares
195,000
Price
—
Value
—
Bashan Dror
PRESIDENT AND CEO · Director
Date
Apr 1
Shares
263,960
Price
—
Value
—
Bashan Dror
PRESIDENT AND CEO · Director
Date
Oct 19
Shares
16,129
Price
$1.41
Value
$23K
Bashan Dror
PRESIDENT AND CEO · Director
Date
Oct 19
Shares
48,387
Price
$1.40
Value
$68K
Bashan Dror
President and CEO · Director
Date
Aug 15
Shares
800,000
Price
—
Value
—
Bashan Dror
President and CEO
Date
Apr 11
Shares
68,000
Price
$1.50
Value
$102K
Bashan Dror
President and CEO · Director
Date
Feb 25
Shares
637,531
Price
—
Value
—
Dexcel Pharma Technologies Ltd.
10 percent owner
Date
Jun 2
Shares
61,211
Price
$2.56
Value
$157K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About PLX insider trading
PLX insider trades
Protalix BioTherapeutics, Inc. (PLX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Bashan Dror (PRESIDENT AND CEO · Director), Bar-Shalev Amos (Director), Schwartz Aharon (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. PLX insiders have been mixed buying and selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Protalix BioTherapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
PLX insider trading · 5 questionsThe insiders of Protalix BioTherapeutics, Inc. (PLX) include executives and directors such as Bashan Dror (PRESIDENT AND CEO · Director), Bar-Shalev Amos (Director), Schwartz Aharon (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026